Critical Survey: Hypertension Diagnostics (OTCMKTS:HDII) & TriSalus Life Sciences (NASDAQ:TLSI)

TriSalus Life Sciences (NASDAQ:TLSI) and Hypertension Diagnostics (OTCMKTS:HDII) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Profitability

This table compares TriSalus Life Sciences and Hypertension Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-206.24%	N/A	-236.83%
Hypertension Diagnostics	N/A	N/A	N/A

Insider and Institutional Ownership

2.6% of TriSalus Life Sciences shares are owned by institutional investors. 32.8% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 40.0% of Hypertension Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares TriSalus Life Sciences and Hypertension Diagnostics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$26.89 million	6.40	-$59.04 million	($2.49)	-2.27
Hypertension Diagnostics	N/A	N/A	N/A	N/A	N/A

Hypertension Diagnostics has lower revenue, but higher earnings than TriSalus Life Sciences.

Volatility and Risk

TriSalus Life Sciences has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Hypertension Diagnostics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for TriSalus Life Sciences and Hypertension Diagnostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	0	0	8	2	3.20
Hypertension Diagnostics	0	0	0	0	0.00

TriSalus Life Sciences currently has a consensus target price of $11.56, suggesting a potential upside of 105.01%. Given TriSalus Life Sciences’ stronger consensus rating and higher probable upside, research analysts clearly believe TriSalus Life Sciences is more favorable than Hypertension Diagnostics.

Summary

TriSalus Life Sciences beats Hypertension Diagnostics on 7 of the 10 factors compared between the two stocks.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

About Hypertension Diagnostics

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.